Clinical trials: Body Weight Control
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.
Weight Management
Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties
The physical properties of a food product, such as its gelling properties in the stomach can influence how full a person may feel after its consumption.
- Trial name
- NCT07127198
- Testing
- Beverage Variant 1 (low gelation properties), Beverage Variant 2 (medium gelation properties), Beverage Variant 3 (high gelation properties)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity
This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without…
- Trial name
- NCT03842501
- Testing
- Release Supplement
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Golo
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation
Overweight or Obesity
A Study of BGM0504 Injection in Participants With Obesity or Overweight
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants.
- Trial name
- NCT06704581
- Testing
- 5 mg BGM0504 injection, 10 mg BGM0504 injection administered subcutaneously (SC) once a week, 15 mg BGM0504 injection
- Where
- China
- Volunteers
- 652 people
- Sponsor
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Obesity or Overweight, Cardiovascular Disease
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-5 (NCT07843472)
- Testing
- Petrelintide
- Where
- 3 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Hoffmann-La Roche
Knee Osteoarthritis, Obesity
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.
- Trial name
- NCT07734311
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
- Trial name
- NCT00709371
- Testing
- Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
- Where
- 20 sites in United States
- Volunteers
- 729 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
- Trial name
- NCT06259981
- Testing
- GLY-200
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Glyscend, Inc.
Type 2 Diabetes Mellitus (T2DM)
Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
This study was aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes program, providing patients with structured diet, exercise plan, group behavioral support and group education.
- Trial name
- NCT02670928
- Testing
- Lifestyle intervention
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Overweight and Obesity
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight.
- Trial name
- NCT06118021
- Testing
- HS-20094
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Obesity or Overweight
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-3 (NCT07843498)
- Testing
- Petrelintide
- Where
- 3 sites in United States
- Volunteers
- 3,900 people
- Sponsor
- Hoffmann-La Roche
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 34 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity, Diabetes
A Study of SYH2069 Injection in Healthy Participants
To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.
- Trial name
- NCT07736391
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Obesity
A Study to Test Different Doses of BI 456906 in Patients With Obesity
Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.
- Trial name
- NCT03591718
- Testing
- BI 456906
- Where
- 2 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Phase 1b Study to Evaluate the Safety of XEN-101
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
- Trial name
- NCT06417697
- Testing
- XEN-101
- Where
- Australia
- Volunteers
- 33 people
- Sponsor
- Xeno Biosciences
Diabetes, Diabetes Mellitus, Type 2
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes…
- Trial name
- DIET™ (NCT01232491)
- Testing
- Insulin detemir, Dietary regimen
- Where
- 112 sites in United States, Argentina and 9 more
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
- Trial name
- NCT07011797
- Testing
- CX11
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Corxel Pharmaceuticals
Obesity
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
- Trial name
- NCT06970405
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals